Published in Stroke on April 08, 2004
International Diabetes Federation guideline for management of postmeal glucose: a review of recommendations. Diabet Med (2008) 1.55
Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes. Cardiovasc Diabetol (2007) 1.18
Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk. Vasc Health Risk Manag (2010) 1.07
Carotid intima-media thickness as a surrogate marker of cardiovascular disease in diabetes. Diabetes Metab Syndr Obes (2011) 1.05
Effects of 24-week treatment with acarbose on glucagon-like peptide 1 in newly diagnosed type 2 diabetic patients: a preliminary report. Cardiovasc Diabetol (2013) 0.99
Anti-hyperglycemic and anti-hyperlipidemic effects of guava leaf extract. Nutr Metab (Lond) (2010) 0.98
Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors. Cardiovasc Diabetol (2010) 0.97
β-cell dysfunction: Its critical role in prevention and management of type 2 diabetes. World J Diabetes (2015) 0.92
Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations. Diabetes Metab Syndr Obes (2012) 0.91
Advances in the treatment of prediabetes. Ther Adv Endocrinol Metab (2010) 0.89
Gender difference in carotid intima-media thickness in type 2 diabetic patients: a 4-year follow-up study. Cardiovasc Diabetol (2012) 0.88
Strategies for optimizing glycemic control and cardiovascular prognosis in patients with type 2 diabetes mellitus. Mayo Clin Proc (2011) 0.87
Prospective, randomized trial on intensive SMBG management added value in non-insulin-treated T2DM patients (PRISMA): a study to determine the effect of a structured SMBG intervention. Acta Diabetol (2011) 0.87
Is hyperglycemia a causal factor in cardiovascular disease? Does proving this relationship really matter? Yes. Diabetes Care (2009) 0.87
Safety and efficacy of acarbose in the treatment of diabetes in Chinese patients. Ther Clin Risk Manag (2014) 0.86
Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study. Vasc Health Risk Manag (2009) 0.85
On the potential of acarbose to reduce cardiovascular disease. Cardiovasc Diabetol (2014) 0.84
American College Of Endocrinology Pre-Diabetes Consensus Conference: part one. Diabetes Care (2008) 0.81
Metabolic syndrome, chronic kidney disease, and cardiovascular disease: a dynamic and life-threatening triad. Cardiol Res Pract (2011) 0.80
Acarbose treatment and the risk of cardiovascular disease in type 2 diabetic patients: a nationwide seven-year follow-up study. J Diabetes Res (2014) 0.78
Acarbose: safe and effective for lowering postprandial hyperglycaemia and improving cardiovascular outcomes. Open Heart (2015) 0.78
Effects of miglitol in platelet-derived microparticle, adiponectin, and selectin level in patients with type 2 diabetes mellitus. Int J Gen Med (2011) 0.77
Acarbose, lente carbohydrate, and prebiotics promote metabolic health and longevity by stimulating intestinal production of GLP-1. Open Heart (2015) 0.77
Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial. Cardiovasc Drugs Ther (2012) 0.77
Effect of Acarbose on Long-Term Prognosis in Acute Coronary Syndromes Patients with Newly Diagnosed Impaired Glucose Tolerance. J Diabetes Res (2015) 0.77
Glucose supply and insulin demand dynamics of antidiabetic agents. J Diabetes Sci Technol (2010) 0.76
Importance of Beta Cell Function for the Treatment of Type 2 Diabetes. J Clin Med (2014) 0.76
Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study. Cardiovasc Diabetol (2016) 0.76
Effect of acarbose to delay progression of carotid intima-media thickness in early diabetes. Diabetes Metab Res Rev (2013) 0.76
Cross-sectional associations between dietary intake and carotid intima media thickness in type 2 diabetes: baseline data from a randomised trial. BMJ Open (2017) 0.75
Insulin as an early treatment for type 2 diabetes: ORIGIN or end of an old question? Diabetes Care (2013) 0.75
Pleiotropic effects of acarbose on atherosclerosis development in rabbits are mediated via upregulating AMPK signals. Sci Rep (2016) 0.75
Cardiovascular Risk in Diabetes Mellitus: Complication of the Disease or of Antihyperglycemic Medications. Clin Pharmacol Ther (2015) 0.75
Cardiovascular effects of anti-diabetes drugs. Expert Opin Drug Saf (2016) 0.75
Evaluation of a Novel Glucose Area Under the Curve (AUC) Monitoring System: Comparison with the AUC by Continuous Glucose Monitoring. Diabetes Metab J (2016) 0.75
Comparison between sitagliptin and nateglinide on postprandial lipid levels: The STANDARD study. World J Diabetes (2013) 0.75
A review of glucagon-like peptide-1 receptor agonists and their effects on lowering postprandial plasma glucose and cardiovascular outcomes in the treatment of type 2 diabetes mellitus. Diabetes Obes Metab (2017) 0.75
Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 5.46
Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 4.38
Insulin secretion and insulin sensitivity pattern is different in isolated impaired glucose tolerance and impaired fasting glucose: the risk factor in Impaired Glucose Tolerance for Atherosclerosis and Diabetes study. Diabetes Care (2003) 1.61
Ala12Ala genotype of the peroxisome proliferator-activated receptor gamma2 protects against atherosclerosis. J Clin Endocrinol Metab (2004) 1.58
Relationship between diurnal blood pressure variation and diurnal blood glucose levels in type 2 diabetic patients. Am J Hypertens (2007) 1.52
Physical training reverses defect in 3-ketoacid CoA-transferase activity in skeletal muscle of diabetic rats. Am J Physiol Endocrinol Metab (2005) 1.40
Extended abdominoperineal excision vs. standard abdominoperineal excision in rectal cancer--a systematic overview. Int J Colorectal Dis (2011) 1.35
Impact of the individual components of the metabolic syndrome and their different combinations on the prevalence of atherosclerotic vascular disease in type 2 diabetes: the Diabetes in Germany (DIG) study. Cardiovasc Diabetol (2007) 1.20
Association of the calpain-10 gene with type 2 diabetes in Europeans: results of pooled and meta-analyses. Mol Genet Metab (2006) 1.14
Factors associated with self and informant ratings of the quality of life of people with dementia living in care facilities: a cross sectional study. PLoS One (2010) 1.12
Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk--the PIOSTAT Study. Metabolism (2007) 1.07
Differential white blood cell count and type 2 diabetes: systematic review and meta-analysis of cross-sectional and prospective studies. PLoS One (2010) 1.06
Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus. Metabolism (2005) 1.05
Investigation of the vascular and pleiotropic effects of atorvastatin and pioglitazone in a population at high cardiovascular risk. Diab Vasc Dis Res (2008) 0.97
Relationship between hypoglycemic episodes and ventricular arrhythmias in patients with type 2 diabetes and cardiovascular diseases: silent hypoglycemias and silent arrhythmias. Diabetes Care (2013) 0.96
Dementia in residential care: education intervention trial (DIRECT); protocol for a randomised controlled trial. Trials (2010) 0.94
Acarbose: oral anti-diabetes drug with additional cardiovascular benefits. Expert Rev Cardiovasc Ther (2008) 0.93
Expanded ligands: bis(2,2':6',2''-terpyridine carboxylic acid)ruthenium(ii) complexes as metallosupramolecular analogues of dicarboxylic acids. Dalton Trans (2007) 0.93
Effect of acarbose on vascular disease in patients with abnormal glucose tolerance. Cardiovasc Drugs Ther (2008) 0.91
Physical disability contributes to caregiver stress in dementia caregivers. J Gerontol A Biol Sci Med Sci (2005) 0.91
A cluster-randomised trial of staff education to improve the quality of life of people with dementia living in residential care: the DIRECT study. PLoS One (2011) 0.89
Current experiences and educational preferences of general practitioners and staff caring for people with dementia living in residential facilities. BMC Geriatr (2009) 0.89
In vivo evidence for increased oxidation of circulating LDL in impaired glucose tolerance. Diabetes (2002) 0.88
Circulating chemerin decreases in response to a combined strength and endurance training. Endocrine (2013) 0.88
Development and evaluation of an educational intervention for general practitioners and staff caring for people with dementia living in residential facilities. Int Psychogeriatr (2010) 0.85
Structured health care for subjects with diabetic foot ulcers results in a reduction of major amputation rates. Cardiovasc Diabetol (2013) 0.85
Leukocyte count and fibrinogen are associated with carotid and femoral intima-media thickness in a risk population for diabetes. Cardiovasc Res (2002) 0.83
Metabolic syndrome and its single traits as risk factors for diabetes in people with impaired glucose tolerance: the STOP-NIDDM trial. Diab Vasc Dis Res (2009) 0.81
Fluctuations in glycaemia in clinical diabetes mellitus type 2 are not associated with carotid intima-media thickening. Diab Vasc Dis Res (2004) 0.81
Conversion of IGT to type 2 diabetes mellitus is associated with incident cases of hypertension: a post-hoc analysis of the STOP-NIDDM trial. J Hypertens (2012) 0.80
Physical training reverses the increased activity of the hepatic ketone body synthesis pathway in chronically diabetic rats. Am J Physiol Endocrinol Metab (2006) 0.78
Nacnac(Bn)CuOiPr: a strained geometry resulting in very high lactide polymerization activity. Chem Commun (Camb) (2012) 0.78
Square-planar Cu(II) diketiminate complexes in lactide polymerization. Inorg Chem (2013) 0.78
'Gotta be sit down and worked out together': views of Aboriginal caregivers and service providers on ways to improve dementia care for Aboriginal Australians. Rural Remote Health (2011) 0.78
Lactide polymerization catalyzed by Mg and Zn diketiminate complexes with flexible ligand frameworks. Dalton Trans (2014) 0.77
Effects of supervised vs non-supervised combined aerobic and resistance exercise programme on cardiometabolic risk factors. Cent Eur J Public Health (2013) 0.77
[Metabolic syndrome: "common soil" for diabetes and atherosclerosis. Novel approaches to an integrated therapy]. Herz (2006) 0.77
Prandial hyperglycemia: is it important to track and treat? Curr Diab Rep (2005) 0.77
Coagulation factor V G allele and HR2 haplotype: factor V activity, activated protein C resistance and risk of venous thrombosis. Blood Coagul Fibrinolysis (2003) 0.76
Pulse pressure is a strong predictor of cardiovascular risk: Data of the risk factors in impaired glucose tolerance for atherosclerosis and diabetes and the Sofia Metabolic Syndrome studies. Folia Med (Plovdiv) (2009) 0.75
Nacnac(Bn)MgOtBu: a diketiminate-based catalyst for the polymerisation of rac-lactide with slight isotactic preference. Dalton Trans (2011) 0.75
Exploring the reactivity of manganese(iii) complexes with diphenolate-diamino ligands in rac-lactide polymerization. Dalton Trans (2015) 0.75
Potential association of paraoxonase-1, type 2 diabetes mellitus, and periodontitis. J Periodontol (2012) 0.75
Exceptionally high lactide polymerization activity of zirconium complexes with bridged diketiminate ligands. Dalton Trans (2012) 0.75
Association of physical activity with insulin resistance, subclinical inflammation, coagulation, and fibrinolytic biomarkers among population at high risk for type 2 diabetes. Folia Med (Plovdiv) (2012) 0.75
[Postprandial hyperglycemia as a risk factor for cardiovascular disease. Therapy improves prognosis]. Herz (2004) 0.75
Intramolecular pi-stacking in copper(I) diketiminate phenanthroline complexes. Dalton Trans (2010) 0.75
A new HPLC-based assay for the measurement of fructosamine-3-kinase (FN3K) and FN3K-related protein activity in human erythrocytes. Clin Chem Lab Med (2014) 0.75
Formation and reactivity of 3-diazopyridinium cations and influence on their reductive electrografting on glassy carbon. Langmuir (2012) 0.75
Physical activity is strongly inversely related to post-challenge plasma glucose and glycemic spikes in a risk population for type 2 diabetes. Folia Med (Plovdiv) (2013) 0.75